Patents by Inventor Takafumi Harada

Takafumi Harada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250034071
    Abstract: Compounds and use of the compounds for formula (I) where X is selected from the group consisting of a single bond, O, N—(C1-C4)-alkyl, N—Ar1, CR5R6, S, S(O) and SO2; Z1 and Z2 are independently selected from hydrogen, -Alk-OH, —CH2—Ar2—CH2—OH, -Alk?-C(O)ORx, —CH2—Ar2—C(O)ORx and —C(O)—Ar2—C(O)ORx, where Rx is selected from the group consisting of hydrogen, phenyl, benzyl and C1-C4-alkyl; R1 and R2 are independently selected from the group consisting of optionally substituted mono- or polycyclic aryl having from 6 to 26 carbon atoms as ring members and optionally substituted mono- or polycyclic hetaryl having a total of 5 to 26 atoms as ring members, R5 is selected from the group consisting of hydrogen, C1-C4-alkyl and a radical Ar1; R6 is selected from the group consisting of hydrogen and C1-C4-alkyl; Alk is C2-C4-alkandiyl; provided that R1 and R2 are not both phenyl, if R3 and R4 are both hydrogen.
    Type: Application
    Filed: September 8, 2022
    Publication date: January 30, 2025
    Applicant: MITSUBISHI GAS CHEMICAL COMPANY, INC.
    Inventors: Noriyuki KATO, Katsushi NISHIMORI, Atsushi MOTEGI, Kentaro ISHIHARA, Shinya IKEDA, Takafumi WATANABE, Tatsunobu OGATA, Kazutaka TAKAMATSU, Yutaro HARADA, Vasyl ANDRUSHKO, Karl REUTER, Philipp KOSCHKER, Florian STOLZ, Mark KANTOR
  • Publication number: 20250019332
    Abstract: The present invention relates to compounds of the formula (I) where X is selected from the group consisting of a single bond, O, N—(C1-C4)-alkyl, N—Ar1, CR5R6, S, S(O) and SO2; Z1 and Z2 are independently selected from hydrogen, -Alk-OH, —CH2—Ar2—CH2—OH, -Alk?-C(O)ORx, —CH2—Ar2—C(O)ORx and —C(O)—Ar2—C(O)ORx, where Rx is selected from the group consisting of hydrogen, phenyl, benzyl and C1-C4-alkyl; R1 and R2 are independently selected from the group consisting of optionally substituted mono- or polycyclic aryl having from 6 to 26 carbon atoms as ring members and optionally substituted mono- or polycyclic hetaryl having a total of 5 to 26 atoms as ring members, R5 is selected from the group consisting of hydrogen, C1-C4-alkyl and a radical Ar1; R6 is selected from the group consisting of hydrogen and C1-C4-alkyl; Alk is C2-C4-alkandiyl; provided that R1 and R2 are not both phenyl, if R3 and R4 are both hydrogen.
    Type: Application
    Filed: September 8, 2022
    Publication date: January 16, 2025
    Inventors: Vasyl ANDRUSHKO, Karl REUTER, Philipp KOSCHKER, Florian STOLZ, Mark KANTOR, Noriyuki KATO, Katsushi NISHIMORI, Atsushi MOTEGI, Kentaro ISHIHARA, Shinya IKEDA, Takafumi WATANABE, Tatsunobu OGATA, Kazutaka TAKAMATSU, Yutaro HARADA
  • Patent number: 11870792
    Abstract: An abnormal traffic analysis apparatus includes receiving means for receiving traffic from a device via any of a plurality of communication paths in which different communication methods are used, multiple communication management means for identifying a communication path through which the traffic is transmitted, analysis method determination means for determining an analysis algorithm for detecting abnormality of the traffic according to the communication path identified by the multiple communication management means, analysis means for analyzing whether or not the traffic is abnormal traffic by using the analysis algorithm determined by the analysis method determination means, and analysis result recording means for recording a result of analysis performed by the analysis means.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: January 9, 2024
    Assignee: NIPPON TELEGRAPH AND TELEPHONE CORPORATION
    Inventors: Takafumi Harada, Gembu Morohashi, Hiroki Ito
  • Patent number: 11553347
    Abstract: An abnormal traffic analysis apparatus includes receiving means for receiving traffic from a device, analysis means for analyzing whether or not traffic received from the device is abnormal traffic, analysis result recording means for recording a result of analysis performed by the analysis means, and device management means for managing movement of the device between edges. If it is determined by the device management means that a device that is a target of analysis performed by the analysis means moves to an edge, the receiving means creates information for continuing analysis of traffic received from the device and transmits the information to an apparatus for analyzing traffic that is included in the edge to which the device moves.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: January 10, 2023
    Assignee: NIPPON TELEGRAPH AND TELEPHONE CORPORATION
    Inventors: Takafumi Harada, Gembu Morohashi, Hiroki Ito
  • Publication number: 20220301422
    Abstract: An anomaly detection system includes a memory and a processor configured to divide a set of data measured in a geographical space into a plurality of groups that represent a plurality of predetermined geographical subspaces, calculate, for each group, a feature amount in the group using data included in the group, and determine whether or not there is a group that is likely to include abnormal data, among the plurality of groups, using the feature amount in each of the plurality of groups.
    Type: Application
    Filed: September 12, 2019
    Publication date: September 22, 2022
    Applicant: NIPPON TELEGRAPH AND TELEPHONE CORPORATION
    Inventors: Takafumi HARADA, Keita HASEGAWA, Tomoaki WASHIO, Yoshihito OSHIMA
  • Publication number: 20220253677
    Abstract: An action learning system includes a memory, and a processor configured to train, based on first data indicating a property of an environment in which data is collected from multiple devices and to which an action determined by a first neural network according to a state of the environment is applied and second data indicating a property of the environment to which the action is not applied, a second neural network that calculates a similarity degree between distributions of the first data and the second data, and train, after the second neural network is trained, the first neural network that determines an action according to the state of the environment, by reinforcement learning including, in a reward, a value that changes based on a relationship between a similarity degree and a parameter set by a user, the similarity degree being calculated by the second neural network based.
    Type: Application
    Filed: July 10, 2019
    Publication date: August 11, 2022
    Applicant: NIPPON TELEGRAPH AND TELEPHONE CORPORATION
    Inventors: Yuichiro DAN, Keita HASEGAWA, Takafumi HARADA, Tomoaki WASHIO, Yoshihito OSHIMA
  • Patent number: 11117187
    Abstract: Disclosed is a casting nozzle intended to suppress or prevent breaking of a nozzle body thereof. The casting nozzle comprises: a nozzle body; a metal casing disposed to surround an upper end of the nozzle body to form a gas pool between an outer peripheral surface of the upper end of the nozzle body and an inner peripheral surface of the metal casing; and a bridging segment provided in at least a part of the gas pool to bridge between the outer peripheral surface of the upper end of the nozzle body and the inner peripheral surface of the metal casing.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: September 14, 2021
    Assignee: KROSAKIHARIMA CORPORATION
    Inventors: Takafumi Harada, Kouichi Tachikawa
  • Publication number: 20210058794
    Abstract: An abnormal traffic analysis apparatus includes receiving means for receiving traffic from a device, analysis means for analyzing whether or not traffic received from the device is abnormal traffic, analysis result recording means for recording a result of analysis performed by the analysis means, and device management means for managing movement of the device between edges. If it is determined by the device management means that a device that is a target of analysis performed by the analysis means moves to an edge, the receiving means creates information for continuing analysis of traffic received from the device and transmits the information to an apparatus for analyzing traffic that is included in the edge to which the device moves.
    Type: Application
    Filed: March 8, 2019
    Publication date: February 25, 2021
    Applicant: NIPPON TELEGRAPH AND TELEPHONE CORPORATION
    Inventors: Takafumi HARADA, Gembu MOROHASHI, Hiroki ITO
  • Publication number: 20210029149
    Abstract: An abnormal traffic analysis apparatus includes receiving means for receiving traffic from a device via any of a plurality of communication paths in which different communication methods are used, multiple communication management means for identifying a communication path through which the traffic is transmitted, analysis method determination means for determining an analysis algorithm for detecting abnormality of the traffic according to the communication path identified by the multiple communication management means, analysis means for analyzing whether or not the traffic is abnormal traffic by using the analysis algorithm determined by the analysis method determination means, and analysis result recording means for recording a result of analysis performed by the analysis means.
    Type: Application
    Filed: March 8, 2019
    Publication date: January 28, 2021
    Applicant: NIPPON TELEGRAPH AND TELEPHONE CORPORATION
    Inventors: Takafumi HARADA, Gembu MOROHASHI, Hiroki ITO
  • Patent number: 10806753
    Abstract: A core-shell gel particle of the invention contains a crosslinked hyaluronic acid, has a higher equilibrium swelling capacity at the surface than at the center, the equilibrium swelling capacity showing a change curve with an inflection point from the center to the surface, and has a probe pushing force of 20 nN or less from the surface to a depth of 800 nm.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: October 20, 2020
    Assignee: Denka Company Limited
    Inventors: Akio Ohno, Masamichi Hashimoto, Harei Nemoto, Takafumi Harada, Kenji Fujii
  • Publication number: 20200108440
    Abstract: Disclosed is a casting nozzle intended to suppress or prevent breaking of a nozzle body thereof. The casting nozzle comprises: a nozzle body; a metal casing disposed to surround an upper end of the nozzle body to form a gas pool between an outer peripheral surface of the upper end of the nozzle body and an inner peripheral surface of the metal casing; and a bridging segment provided in at least a part of the gas pool to bridge between the outer peripheral surface of the upper end of the nozzle body and the inner peripheral surface of the metal casing.
    Type: Application
    Filed: June 19, 2018
    Publication date: April 9, 2020
    Applicant: KROSAKIHARIMA CORPORATION
    Inventors: Takafumi HARADA, Kouichi TACHIKAWA
  • Patent number: 10449212
    Abstract: Provided is an immunostimulating oligonucleotide that is suitable for industrial production and has an excellent type-I IFN inducing activity even when not modified to become a phosphorothioate. This linear double-stranded oligonucleotide contains 10-100 base pairs, wherein the single-stranded oligonucleotides constituting the double-stranded oligonucleotide each contain 2-20 phosphodiester-mediated cytosine-guanine (CpG) sequences, and at least 90% of the internucleotide bonds in each single-stranded oligonucleotide are phosphodiester bonds.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: October 22, 2019
    Assignees: NATIONAL INSTITUTE FOR MATERIALS SCIENCE, DENKA COMPANY LIMITED
    Inventors: Nobutaka Hanagata, Hiroshi Otsuka, Takafumi Harada
  • Patent number: 10421760
    Abstract: Provided are a novel compound or a salt thereof, and a pharmaceutical composition comprising the same, which selectively and strongly inhibit JAK3, exhibit an excellent activity for suppressing the growth of human peripheral blood monocytes and an excellent oral absorbability, and exhibits an activity of inhibiting IL-2-induced IFN-? production in vivo. A compound represented by formula (I) [wherein X represents —CH?CH—, —NH—, a sulfur atom or an oxygen atom; and n represents an integer of 0 to 2], or a salt thereof.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: September 24, 2019
    Assignee: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Masayuki Nakamura, Hiroyoshi Yamanaka, Morihiro Mitsuya, Takafumi Harada
  • Publication number: 20180333430
    Abstract: A core-shell gel particle of the invention contains a crosslinked hyaluronic acid, has a higher equilibrium swelling capacity at the surface than at the center, the equilibrium swelling capacity showing a change curve with an inflection point from the center to the surface, and has a probe pushing force of 20 nN or less from the surface to a depth of 800 nm.
    Type: Application
    Filed: July 31, 2018
    Publication date: November 22, 2018
    Applicant: DENKA COMPANY LIMITED
    Inventors: Akio OHNO, Masamichi HASHIMOTO, Harei NEMOTO, Takafumi HARADA, Kenji FUJII
  • Publication number: 20180208598
    Abstract: Provided are a novel compound or a salt thereof, and a pharmaceutical composition comprising the same, which selectively and strongly inhibit JAK3, exhibit an excellent activity for suppressing the growth of human peripheral blood monocytes and an excellent oral absorbability, and exhibits an activity of inhibiting IL-2-induced IFN-? production in vivo. A compound represented by formula (I) [wherein X represents —CH?CH—, —NH—, a sulfur atom or an oxygen atom; and n represents an integer of 0 to 2], or a salt thereof.
    Type: Application
    Filed: July 29, 2016
    Publication date: July 26, 2018
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Masayuki NAKAMURA, Hiroyoshi YAMANAKA, Morihiro MITSUYA, Takafumi HARADA
  • Publication number: 20180193371
    Abstract: Provided is an immunostimulating oligonucleotide that is suitable for industrial production and has an excellent type-I IFN inducing activity even when not modified to become a phosphorothioate. This linear double-stranded oligonucleotide contains 10-100 base pairs, wherein the single-stranded oligonucleotides constituting the double-stranded oligonucleotide each contain 2-20 phosphodiester-mediated cytosine-guanine (CpG) sequences, and at least 90% of the internucleotide bonds in each single-stranded oligonucleotide are phosphodiester bonds.
    Type: Application
    Filed: July 8, 2016
    Publication date: July 12, 2018
    Inventors: Nobutaka HANAGATA, Hiroshi OTSUKA, Takafumi HARADA
  • Patent number: 9782392
    Abstract: A method for treating rheumatoid arthritis, multiple sclerosis, or a disease involving JAK3, including administering a compound of the formula (I) or a salt thereof to a subject
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: October 10, 2017
    Assignee: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Masayuki Nakamura, Hiroyoshi Yamanaka, Kazuaki Shibata, Morihiro Mitsuya, Takafumi Harada
  • Patent number: 9676773
    Abstract: Provided is a novel compound having a selective JAK3-inhibitory effect and also having excellent oral absorbability. Also provided is a pharmaceutical agent, which is based on a JAK3-inhibitory effect and is useful for preventing and/or treating a disease involving the JAK3, and in particular, rheumatoid arthritis or multiple sclerosis. An azaindole derivative having a cycloalkenyl group, which is represented by the following formula (I), or a salt thereof, and a pharmaceutical composition containing the same: where R1 to R4, m and n have the same meanings as those defined in the description.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: June 13, 2017
    Assignee: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Masayuki Nakamura, Hiroyoshi Yamanaka, Kazuaki Shibata, Morihiro Mitsuya, Takafumi Harada
  • Publication number: 20170119743
    Abstract: A method for treating rheumatoid arthritis, multiple sclerosis, or a disease involving JAK3, including administering a compound of the formula (I) or a salt thereof to a subject
    Type: Application
    Filed: January 12, 2017
    Publication date: May 4, 2017
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Masayuki NAKAMURA, Hiroyoshi YAMANAKA, Kazuaki SHIBATA, Morihiro MITSUYA, Takafumi HARADA
  • Publication number: 20160340353
    Abstract: Provided is a novel compound having a selective JAK3-inhibitory effect and also having excellent oral absorbability. Also provided is a pharmaceutical agent, which is based on a JAK3-inhibitory effect and is useful for preventing and/or treating a disease involving the JAK3, and in particular, rheumatoid arthritis or multiple sclerosis. An azaindole derivative having a cycloalkenyl group, which is represented by the following formula (I), or a salt thereof, and a pharmaceutical composition containing the same: where R1 to R4, m and n have the same meanings as those defined in the description.
    Type: Application
    Filed: February 4, 2015
    Publication date: November 24, 2016
    Applicant: TAIHO PHARMARCEUTICAL CO., LTD.
    Inventors: Masayuki NAKAMURA, Hiroyoshi YAMANAKA, Kazuaki SHIBATA, Morihiro MITSUYA, Takafumi HARADA